View in EDS HTML Full Text PDF Full Text

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

Saved in:
Bibliographic Details
Title: HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Authors: Pohlmann PR; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Graham D; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA., Wu T; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Ottaviano Y; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Mohebtash M; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Kurian S; Medstar Franklin Square Medical Center, Baltimore, MD, USA., McNamara D; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA., Lynce F; Dana-Farber Cancer Institute, Boston, MA, USA., Warren R; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Dilawari A; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA., Rao S; Medstar Franklin Square Medical Center, Baltimore, MD, USA., Mainor C; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Swanson N; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Tan M; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA., Isaacs C; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA., Swain SM; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. sandra.swain@georgetown.edu.; MedStar Health, Washington, DC, USA. sandra.swain@georgetown.edu.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Dec; Vol. 196 (3), pp. 571-581. Date of Electronic Publication: 2022 Oct 25.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36280642
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pohlmann+PR%22">Pohlmann PR</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Graham+D%22">Graham D</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Ottaviano+Y%22">Ottaviano Y</searchLink>; Medstar Franklin Square Medical Center, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Mohebtash+M%22">Mohebtash M</searchLink>; Medstar Franklin Square Medical Center, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kurian+S%22">Kurian S</searchLink>; Medstar Franklin Square Medical Center, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22McNamara+D%22">McNamara D</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Hackensack University Medical Center, Hackensack, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lynce+F%22">Lynce F</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Warren+R%22">Warren R</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Dilawari+A%22">Dilawari A</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rao+S%22">Rao S</searchLink>; Medstar Franklin Square Medical Center, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Mainor+C%22">Mainor C</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; MedStar Georgetown University Hospital, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Swanson+N%22">Swanson N</searchLink>; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Tan+M%22">Tan M</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Isaacs+C%22">Isaacs C</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.; Clinical Research Management Office, Georgetown University Medical Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Swain+SM%22">Swain SM</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. sandra.swain@georgetown.edu.; MedStar Health, Washington, DC, USA. sandra.swain@georgetown.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2022 Dec; Vol. 196 (3), pp. 571-581. <i>Date of Electronic Publication: </i>2022 Oct 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36280642
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-022-06743-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 571
    Titles:
      – TitleFull: HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pohlmann PR
      – PersonEntity:
          Name:
            NameFull: Graham D
      – PersonEntity:
          Name:
            NameFull: Wu T
      – PersonEntity:
          Name:
            NameFull: Ottaviano Y
      – PersonEntity:
          Name:
            NameFull: Mohebtash M
      – PersonEntity:
          Name:
            NameFull: Kurian S
      – PersonEntity:
          Name:
            NameFull: McNamara D
      – PersonEntity:
          Name:
            NameFull: Lynce F
      – PersonEntity:
          Name:
            NameFull: Warren R
      – PersonEntity:
          Name:
            NameFull: Dilawari A
      – PersonEntity:
          Name:
            NameFull: Rao S
      – PersonEntity:
          Name:
            NameFull: Mainor C
      – PersonEntity:
          Name:
            NameFull: Swanson N
      – PersonEntity:
          Name:
            NameFull: Tan M
      – PersonEntity:
          Name:
            NameFull: Isaacs C
      – PersonEntity:
          Name:
            NameFull: Swain SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2022 Dec
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 196
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1